<DOC>
	<DOCNO>NCT02542254</DOCNO>
	<brief_summary>This study evaluate addition RPL554 standard reliever medication chronic obstructive pulmonary disorder ( COPD ) . All patient receive six treatment randomise sequence : 1. salbutamol , 2. ipratropium , 3. salbutamol + RPL554 , 4. ipratropium + RPL554 , 5 . RPL554 6 . Placebo</brief_summary>
	<brief_title>The Effects RPL554 Top Standard COPD Reliever Medications</brief_title>
	<detailed_description>The purpose study investigate RPL554 additive bronchodilator effect administer combination standard care bronchodilator patient COPD.This study investigate pharmacodynamic effect RPL554 use spirometry whole body plethysmography compare placebo , administer addition beta2 agonist ( salbutamol ) , muscarinic antagonist ( ipratropium ) placebo .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Provide inform consent Males donate sperm use adequate contraception female surgically sterile postmenopausal 12lead ECG showing : Heart rate 45 90 bpm , QTcF≤450 msec , QRS ≤120 msec , PR interval ≤220 msec , clinically significant abnormality Capable comply study restriction procedure include ability use study nebuliser correctly . BMI 18 33 kg/m2 minimum weight 45 kg . COPD diagnosis least 1 year clinically stable COPD previous 4 week Demonstrates reversibility bronchodilator ( two puff salbutamol follow two puff ipratropium ) via spirometry : Postbronchodilator FEV1/forced vital capacity ( FVC ) ratio ≤0.70 Postbronchodilator FEV1 ≥40 % ≤80 % predict normal ≥150 mL increase prebronchodilator FEV1 Chest Xray show abnormality Meet concomitant medication restriction expect rest study . Smoking history ≥10 pack year . Capable withdraw long acting bronchodilator throughout study short act bronchodilator 8 hour prior study treatment . History lifethreatening COPD include Intensive Care Unit admission and/or require intubation . COPD exacerbation require oral steroid previous 3 month History one hospitalisation COPD previous 12 month Respiratory tract infection ( upper low ) treat antibiotic previous 12 week Evidence cor pulmonale clinically significant pulmonary hypertension . Other respiratory disorder Previous lung resection lung reduction surgery . Oral therapy COPD previous 3 month throughout study . Drug alcohol abuse past 3 year Received experimental drug within 3 month five half life , whichever longer . Prior exposure RPL554 Patients history chronic uncontrolled disease Investigator believe clinically significant . Documented cardiovascular disease last 3 month Major surgery , ( require general anaesthesia ) previous 6 week , fully recover surgery , plan surgery end study . History malignancy organ system within 5 year exception localise skin cancer ( basal squamous cell ) Clinically significant abnormal value safety laboratory test A disclosed history , one know Investigator , significant non compliance previous investigational study prescribe medication . Requires oxygen therapy , even occasional basis . Inability adequately perform whole body plethysmography . Any reason Investigator considers make subject unsuitable participate . Patients know hypersensitivity atropine derivative , ipratropium bromide , salbutamol RPL554 excipients/components .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>